Mucolytics and anti-inflammatory lung treatments

F. Ratjen (Toronto, Canada)

Source: ERS course 2015
Number: 4

PDF journal article, handout or slidesSlide presentation

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
F. Ratjen (Toronto, Canada). Mucolytics and anti-inflammatory lung treatments. ERS course 2015

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Anti-inflammatory therapies in bronchiectasis
Source: Eur Respir Mon 2011; 52: 223-238
Year: 2011

Next generation of anti-inflammatory therapy for COPD?
Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017
Year: 2017

Changes in the anti-inflammatory treatment of COPD
Source: Annual Congress 2012 - PG9 Progress on the treatment of COPD
Year: 2012

Macrolides as anti-inflammatory agents in CAP
Source: Eur Respir Monogr 2014; 63: 243-255
Year: 2014

Update on anti-inflammatory therapy in asthma
Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease
Year: 2012

Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001

Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1702033; 10.1183/13993003.02033-2017
Year: 2018

Macrolides, mucoactive drugs and adherence for the management of bronchiectasis
Source: Eur Respir J, 51 (1) 1701987; 10.1183/13993003.01987-2017
Year: 2018

Cardioprotective effects of inhaled corticosteroid-containing combination therapy in COPD
Source: Eur Respir J, 53 (2) 1802420; 10.1183/13993003.02420-2018
Year: 2019

Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs
Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases
Year: 2021

HDAC2-independent anti-inflammatory effects of budesonide in human lung fibroblasts
Source: Annual Congress 2011 - Recent developments in COPD
Year: 2011

Anti-inflammatory effects of targeted lung denervation in patients with COPD
Source: Eur Respir J 2015; 46: 1489-1492
Year: 2015

Azithromycin in the anti-inflammatory treatment of children with asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 167s
Year: 2004

Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids?
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007

Advantageous toxicity profile of an inhaled GATA-3-specific DNAzyme intended for anti-inflammatory treatment of Th2-driven asthma
Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD
Year: 2012

Do long-acting β2-adrenoceptor agonists enhance the anti-inflammatory effect of glucocorticoids in asthma?
Source: Eur Respir J 2001; 17: 1059-1061
Year: 2001

Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012

Persistency of antioxidant/antiinflammatory effects of erdosteine treatment in COPD
Source: Annual Congress 2009 - Drug effects in COPD
Year: 2009